AbCellera Biologics Inc Investor Event Transcript, Nov 17, 2026
AbCellera Biologics Inc. (ABCL)
AbCellera says its phase two ABCL635 hot flash trial showed roughly twice the frequency reduction of small-molecule NK3R antagonists at four weeks; 12-week data is due early 2027. AI summary
Conference Transcript - ABCL 2026-11-17
Alice Nettleton, Analyst — UBS
Welcome to the next session at the UBS Biopharma Conference in London. I'm Alice Nettleton, one of the U.S. SMID biotech analysts at UBS. Happy to introduce Abselera. We have with us Carl Hansen, CEO. Thank you so much for joining us.
Carl Hansen, CEO
Thanks, Alice. It's a pleasure to be here.
Alice Nettleton, Analyst — UBS
So just to start then, maybe we can start off with a brief overview of AppSellera for those who might be newer to the story, and you can cover the exciting data that you had earlier this year, and then we can move to some Q&A.
Carl Hansen, CEO
Okay, great. I'll try to keep it short and punchy. So AppSellera is a biotech company. We're located in Vancouver, British Columbia. We're about 14 years old. The company, you know, through the first 10 years, we were very much focused on building best-in-world technology for solving difficult antibody discovery problems. And through that, we have put in place a platform that I think has conspicuous advantages in some important areas of antibody therapeutics, in particular targeting GPCRs and ion channels, and more recently, you know, gaining a lot of traction in T-cell engagers. The first 10 years of the company, the business model was not the classic biotech. It was being hired guns for big pharma and biotech. So we had to cut our teeth solving the problems that others couldn't solve. We had a big success with COVID-19, which resulted in a couple therapeutics that were brought to the market by Eli Lilly. Shortly after that, we went public. And through the result of that, we're able to bring in about, you know, about 1.5 billion or so that funded a build out of the platform. to what is now a full end-to-end capability for antibody therapeutics. In 2023, we made the decision to switch gears in the business model and to pursue the more classic biotech approach of developing our own drugs. So we have a large discovery pipeline, and over the last three years, we have been retooling the company to bring that into the clinic. Just this last year, we had our first two that went into the clinic. One was an OX40 ligand half-life extended antibody that was a little bit opportunistic that came from an earlier partnership. I read out last week, it looks great, but we decided to discontinue it just based on what's happened in the class. And as you alluded to, the most exciting program is the lead asset, ABCL635, which is a first-in-class antibody antagonist of NK3R, a GPCR target. And it's being developed for the non-hormonal treatment of vasomotor symptoms or hot flashes associated with menopause or associated with hormone deprivation that is given in the treatment of breast cancer or prostate cancer. So we brought that into clinic about a year and a half ago. And in August, we had our phase two readout that just blew the doors off with efficacy that is roughly twice as good in reducing the frequency of hot flashes over the current market leaders, which are small molecule NK3R antagonists, and about four to five times as good in severity and with a clean safety profile. So we think we have a very exciting opportunity to develop what will be a landmark in redefining medicine for the non-hormonal treatment of hot flashes, and we are currently preparing to scale up and put that into late-stage studies next year.
Alice Nettleton, Analyst — UBS
Great. Thank you for that overview. So maybe just digging a bit more into that four-week data update. For people who are maybe less familiar with this indication, because it's quite a new area for investors, can you explain what are the key takeaways from that data, and then what does it indicate about the potential differentiation? You mentioned safety and efficacy.
Carl Hansen, CEO
Sure. So obviously, everyone is familiar with hot flashes. These are the most problematic symptom for women that are going through perimenopause and menopause. Uh, and essentially they are, you know, episodes where you have, you know, a sudden, you know, flushing increase in temperature, uh, in high severity, you end up, you know, breaking a sweat, sometimes having to stop what you do, sometimes having to change clothing. Um, it ends up being a very disruptive symptom, uh, for women at an important time in their lives. Uh, and it's a symptom that can last for a long time. The median time for hot flashes is about seven years. Um, Recently, there's been a huge uptick in interest in treating hot flashes and in women's health, most notably from removal of the box warning on hormone products that happened just over a year ago, I believe, and the result has been a major change in expectation from women that they should be getting care and that they're expecting to be getting care. Now, the opportunity that we're going after is not to replace hormone therapy, but rather that there's quite a large population of women that are either contraindicated for hormone therapy or that can't tolerate it, and there are very few good options. The most recent options are these small molecule NK3R antagonists, one that has been developed by Estellus and another by Bayer, Linquit and Biosa are their names. One has been on the market now about three years, one just a year. And so those were the leaders that we were following. So in our readout, we showed that at four weeks, so a single dose and then at four weeks, that in terms of reducing the frequency, the number of moderate to severe events, from a baseline of 10, we were able to get, you know, over an 80% total reduction and about a 50% reduction over placebo. There's quite a placebo response because of enrollment. And that compares to 20% or 25% for the small molecules, so about twice the frequency efficacy. The other measure is severity. So a measure of one means you had a hot flash, but it wasn't really a big deal. Two means you had to interrupt what you were doing. And three means that there's been perspiration and you have to change your clothes. It's like a very disruptive event. So from that perspective, we reduced it from 2.5, which is about half moderate, half severe, to 1, which is a mild event. And as I mentioned, that's about four to five times the effect that was seen with small molecules. And so we've done that with a safety profile that is clean. And that's important because both small molecules have a warning for elevated liver enzymes, a potential liver injury, and both of those require liver monitoring as part of therapy. So our objective here is to have a product that is more convenient, once-monthly dosing versus daily oral, that doesn't have a liver toxicity side effect and is safer, and importantly, that has much better efficacy. And the efficacy that I mentioned is not just way better than the small molecules, it's on par or superior to trials that have been done with hormone therapy. So really, you know, the kind of clinical data that you very rarely see in a biotech, and to have that as the lead program on a GPCR target, it's just a terrific spot. So we're pretty pumped.
Alice Nettleton, Analyst — UBS
Definitely, I completely agree. So your next update for this program, you're having a 12-week and OpenABLE extension data update, which you recently confirmed will occur in early 2027. So this is kind of the next big news for you. Perhaps you could remind us, firstly, what is the design from the phase two trial with the four-week and the 12-week and the goal from the 12-week and open-label extension portions?
Carl Hansen, CEO
I'm glad you asked that because the design's a little bit unusual and there's a risk that people misinterpret it. So I've been vigilant to remind people exactly what we're doing here and what we expect. So the trial was a single dose of 600 milligrams of ABCL 635, and it was a double-blind, placebo-controlled trial with 92 women. We measured efficacy at four weeks, and that is one of the registrational endpoints. So it's the right patient population, placebo-controlled, the same enrollment criteria, and one of the key endpoints. And then after that, we are monitoring the patients for an additional eight weeks. So the 12-week data is the last eight weeks of this trial, where they haven't had another dose. Now, this last eight weeks, we're not expecting to see an increase in efficacy. In fact, we're expecting a decrease in efficacy as the antibody washes out. And the reason that we're doing that is that in this particular indication, there's a very tight... Temporal correlation between target engagement and the benefit. So we can build up a precise dose response relationship as the antibody washes out. And then we will use that dose response relationship through the FDA's MIDD program, which is a model informed drug design, drug development design program, which allows you to use, you know, analytical PKPD modeling to predict a phase three dose and to get alignment on the phase three. So this 12-week data, what you're going to see is a diminishing of efficacy in the active group, and then we're also going to combine that with the open-label extension where both the placebo group and the active group have the option to have another single dose of 600 milligrams, and then we'll be measuring efficacy at four weeks again, and that'll be interesting to see, you know, a second dose in the active group and a first dose in the placebo group. After you've had the placebo effect wash out through the first 12 weeks.
Alice Nettleton, Analyst — UBS
Okay.
Carl Hansen, CEO
Okay.
Alice Nettleton, Analyst — UBS
And the dose that was the initial dose, was that 600 milligrams?
Carl Hansen, CEO
That's right, yes.
Alice Nettleton, Analyst — UBS
Okay. And then how could that dose or the dosing interval change in the phase three? Would it be the maintenance dose that changes and maybe the interval, or how should we think about that?
Carl Hansen, CEO
Yeah, so the target product profile we began was to have a loading dose followed by a once-monthly self-administered auto-injector that's a single shot. We have the antibody formulated at 150 mg per ml, and an auto-injector will typically give you a 2 ml injection, so that's a 300 mg shot. And the 600 mg was chosen because if you give 300 mg monthly and you have a half-life of roughly a month, which we do, Then you accumulate drug to a level that's equal to a first shot of 600 milligrams. So to be clear, the 600 milligrams is to simulate the steady state dose on the maintenance dose of 300 milligram. Now, in the trial, I wish I could put up the data because the data speaks for itself, but what we saw was a very rapid response, actually even better than the small molecules on the first week, and a response that continues to go down for four weeks and didn't start to rise at the four-week period. So it is possible that when we look at the full data, we'll decide that we don't need to have a full 300 milligrams every month, we could have a lower dose every month. But that will, and that'll change cost of goods. And we may well decide even to take two doses into phase three. But it doesn't change the fact that we believe we've met the product profile, and we've got a product we can take forward on a once monthly schedule.
Alice Nettleton, Analyst — UBS
So would you say the more important data points for investors might be the repeat dose aspects of the update, or what should we be looking for here?
Carl Hansen, CEO
Yeah, I mean, I would characterize it largely as confirmatory. I mean, the data was so great. So that what we're expecting and hoping is that we see a response on the second dose that looks very much like the first dose. So we will get the first repeat dosing on the active, and the hope is that you get down to frequency and severity levels that look the same as you got at the four-week period on the first dose. Uh, we'll also have, that's also a second dose. There's a little bit of accumulation, uh, not a huge amount. So it's possible we'll do even better on that if there's still some, some room. And then on the placebo arm, uh, you know, it'll be interesting to see that once you've washed out the placebo response, which I attribute largely to reversion to the mean, because when you're enrolling, uh, you're looking for the people that the highest levels, and then there's going to be some reversion after they start the trial. And I think that's a large part of the placebo response. So after that is gone, when you give them their first dose, what you're hoping for is that it looks just like the efficacy of the active arm to start. And that is what we hope, and I think confirming that would be very exciting. Probably even more important is to maintain the clean safety profile. So I mentioned we have seen no sign of elevated liver enzymes, so that's very positive and differentiating. The small molecules also had GI toxicity. We saw no GI toxicity in the four-week readout. In fact, the placebo had higher symptoms there. And apart from that, we had some mild headache that seemed to be mostly at the early part of the trial. So there is a question as to whether that will happen again if you dose a second time or if you've kind of watched that through as a single event. But that's what we're looking for.
Alice Nettleton, Analyst — UBS
And on the ADAs, that was pretty low, so what level of ADAs would still be sort of acceptable with this?
Carl Hansen, CEO
Great question. So we haven't released levels of ADAs. What we have said is that we haven't seen anything that gives us concern, and I can confirm that we're still not expecting any problems with that, and we'll do our best to give more detail on that early next year when we release it.
Alice Nettleton, Analyst — UBS
Okay. And then in terms of next steps after this update early 27, firstly, what level of detail will you provide? Will it be kind of a detailed press release with all the data, or how are you thinking about that?
Carl Hansen, CEO
That's a good question. I think we certainly will provide a press release, and if not right then and shortly after we're at one in earnings call, we would walk through the data completely in a very similar way that we did with the four-week data to make sure we get it all on the table. Yeah. The other important event will be, you know, once that data is in hand, and we've already sort of begun this, we'll be having, you know, post-phase meetings and engaging with regulators and start to get a really clear line of sight as to what will be the development path, both for menopausal VMS and also for the prostate cancer indication and the breast cancer indication. And when we have that in place, I think we'll have, you know, an event to make sure we have a fulsome disclosure so that people see what's coming with that product.
Alice Nettleton, Analyst — UBS
Okay. So how quickly do you think you could start a phase three program in menopause VMS?
Carl Hansen, CEO
Yeah, I've been asked that. We haven't given direct guidance. I would say mid-ish next year is what we're currently targeting, and there's two parts that have to come together. One is we have to get good alignment with regulators, and the second part is that we have to get the CMC in place to begin those trials. We currently have, you know, parallel efforts to set that up either with a pre-filled syringe or with an auto-injector. If the auto-injector is ready, I think we would start with the auto-injector. If not, we would do pre-filled syringe and then bridge. But either way, we're going to move that as quickly as possible into those studies.
Alice Nettleton, Analyst — UBS
Sounds good. And given the strength of the phase two efficacy so far, how are you thinking about the bar for phase three, especially with the comparison to the orals in phase three? What do you think is the minimum you need to show on efficacy and safety to remain sufficiently differentiated?
Carl Hansen, CEO
A great question. The first thing I'll say is if you look at the phase two and phase three developments in the class of the small molecules, there's been a very good preservation of effect size from phase two to phase three. That's not always the case, but in this case, that's translated very well. We're expecting something similar. You always get some erosion into phase three. You've got more patients, less control, but we are expecting, you know, to preserve the large efficacy difference over the small molecules. For us, you know, when we started this, the target product profile was to be differentiated on safety equal in efficacy. Now that we've seen, you know, such a big efficacy difference, obviously our bar has changed, and we want to make sure that we're better. And we haven't put a number on it, but I like to say it's like when you look across the room at the graph, you can tell that it's better without doing a statistical analysis. So I don't know if you're going to call that 50% better or more placebo-adjusted. I think we'd be about right.
Alice Nettleton, Analyst — UBS
Okay, great. And in terms of your phase three program, you've had some questions around if you would do a head-to-head study, maybe against an oral NK3R. I'm not sure if you could do against hormone therapy as well, but can you talk about some reasons for and against running such a trial?
Carl Hansen, CEO
Well, the reasons against are mostly that it adds, you know, execution complexity. That's the first reason. The second reason is that it's not entirely clear what the right comparator would be. And in addition to the two small molecule, NK3R antagonists, there are also other therapies that are used for non-hormonal treatment of VMS that are currently being used, you know, at a comparable frequency, at least, and that includes SSRIs and SNRIs. So, you know, if we were to do a head-to-head, I think it might well be something like ABCL 635 against, you know, physicians' choice of non-hormonal therapies.
Alice Nettleton, Analyst — UBS
Okay.
Carl Hansen, CEO
And that's something that we would consider doing not as part of the registrational study but alongside of it. You know, in terms of the pro case, I think the main case to do something like that would be for pricing discussions, you know, given where we are and how we expect this to proceed through phase three, I don't think there's going to be a big need to have a head-to-head to convince someone that it works better. It's one of these cases where you've got this big difference, but there are jurisdictions where, you know, they're a bit more finicky in terms of the evidence for that, and so that could be a reason to do it. The last thing you said is versus hormone therapy. I think we probably would not do that, in part because we're not positioning this as a substitute for hormone therapy. And even more, hormone therapy is not one thing. There's any number of different products, and they work different for different people. So you would also find yourself, again, with this question of exactly what is the comparator, and then how are you thinking about side effects and risks associated with that as well.
Alice Nettleton, Analyst — UBS
Okay, that's helpful. Maybe we can talk about the commercial opportunity, because that's a big focus as well for investors, obviously. You've provided some really useful market sizing figures for the US in terms of number of patients and how big you think this opportunity could be. I think that's as of 2026. So maybe you could talk about how big you think the TAM could be in menopause, BMS, over time, maybe by 2035, for example. I don't know if you've run those numbers. It's a tricky question.
Carl Hansen, CEO
I'm not sure I can give you like a direct answer, but I could I could sort of, you know, point out some of the levers that make this a very exciting opportunity. You know, some of the some of the early description that we've given is that in the U.S. alone at any given time, we believe there's roughly 12 million women with moderate to severe BMS. Uh, so of that group, uh, we expect there's about 20% that are either contraindicated, uh, or that can't tolerate hormone therapy, right? So call that, you know, uh, 2.2 million or so. Um, so that's, that's already a market opportunity where you're not competing against the hormones. Um, the current list price or the current net price of the small molecules is about $5,000. Uh, so that's about a $12 billion TAM. You know, you might take a cut and say half people go get treatment, then it's six billion. So that's already a very exciting market. With the efficacy, we now think that we will have a bigger share of that market than we otherwise would have. But we also think there's a compelling opportunity for the women that could use hormone therapy but either do not get sufficient relief or who decide that they don't want to take hormone therapy, either because of some adverse events they don't like or because they decide they don't want even the perception or the reality of a greater risk of oncology or of clotting. And there's not a small number of women that feel that way for good reason. So there's an 80% of women there. You know, if you captured even a quarter of that that decided to take this option, you'd basically double the market opportunity. So if it was 12 billion, it'd be 24. And again, that's all in the U.S. On top of that, there are interesting, exciting opportunities for oncology. You know, roughly there's 4 million women that have had or have survived breast cancer. Uh, some fraction of those are going to be on hormone therapy, on anti-hormone therapy that have hot flashes, uh, maybe a quarter, that's a million, roughly the same on the prostate cancer side. Um, so those are significant markets. And then if you can take the product outside the U S, uh, you can add another, you know, 60% or so to that total market opportunity. So I'm not going to say the number cause you build it up. It's very big, but you would expect it to be big. I mean, menopause is not a rare condition. There's half the people on the planet that are going to have it. And for a significant number of them, It's a problem, and for a significant number of those, the current solutions are inadequate.
Alice Nettleton, Analyst — UBS
And does your current estimate include perimenopause or just postmenopause?
Carl Hansen, CEO
Yeah, that has not included perimenopause. That's definitely a population that we're going to look at. Those women have not been included in the trials to date, partly because we're trying to stay quite well aligned with the previous trials, and partly because there's additional preclinical work that needs to be done to support that. But we think it's an exciting opportunity and a great time to engage with women when they're finally realizing they have the issue. and not having to deal with it for multiple years before you find a solution.
Alice Nettleton, Analyst — UBS
That makes sense. I do want to talk about DTC, but firstly, do you have a view on why the oral NK3R uptake isn't higher besides perhaps efficacies being limited and liver safety monitoring? I'm just wondering if there are any factors that limit their uptake that could also apply to you?
Carl Hansen, CEO
Uh, it's a great question. So, you know, the first thing I'd say is the two small molecules, the ozone liquid, they're very important drugs. Um, so there's, there's a large unmet need and this is, you know, the first innovation that we've seen in a long time. Uh, I think, you know, together, and this is a rough estimate, uh, you know, maybe they're annualizing to 400 million or so this year. So for the ones in their third year, ones in the first year. So for the, let's say two and a half Half-year cycle of a drug, that's a pretty good launch, actually, and they're going to be, it's going to be a blockbuster class, clearly. So on that front, it's bullish. It has been, I'd say, rather disappointing compared to some of the projections and compared to the large size of the unmet need. Much of that, we believe, has to do with, you know, the dynamics of drug access and payer interactions. You know, Vioza, Astellas was slow in getting coverage. They have good coverage now, but the coverage is also, you know, quite controlled. So, you know, there are some requirements of having failed hormone therapy and in some cases, you know, have tried SSRIs as well. And I think that is because of the, you know, suboptimal efficacy and the safety liabilities. So BIOZA, which is the furthest advanced, of course, has the liver warning and intense liver monitoring, which is difficult for physicians. And then post-launch, they got a boxed warning because of liver injury. And then they're more expensive to a product that SSRIs that have been used, which is now generic and cheap and easy to prescribe. And I think that has been part of the friction. That said, we think the small molecules are going to end up being blockbuster drugs, and we think we've got a therapy that will do much better than the combination of those two.
Alice Nettleton, Analyst — UBS
And just to follow up on that, do you think you can avoid those access issues because you have a better profile? You might have a higher price, but do you think overall you can avoid that, especially if you do a head-to-head study, I guess?
Carl Hansen, CEO
Yeah, the higher price is a good point because I could have mentioned that as well on the market side because all that was based on the small molecule prices. Our view is that the challenge and access has to do with the combination of efficacy and safety, and we expect to be much more efficacious and safer, provided that we can hold this profile through to phase three. So from that perspective, we don't think we'd be subject to the same limitations, but I'd be hesitant to speculate on future interactions. You never know how it's going to go. But from a purely rational basis, a much, much safer drug that has way better efficacy than anything else that's available seems like something that women should have access to and that we'll hopefully demand access to.
Alice Nettleton, Analyst — UBS
Great. Specialists seem quite excited about this, but how do you see potential in the primary care setting, which is presumably going to be a larger prescriber base, and also DTC, which could be quite large also?
Carl Hansen, CEO
Yeah, I'm glad you brought up DTC because I think that's one of the most exciting parts of this drug, and I'll mention that in a second. So I think if you look back a few years, the large majority of menopause care was happening from OBGYNs, maybe 80%, 20%. I think that is shifting. I think there's a greater and greater participation from primary care, and probably a big part of that is that there's been an awakening of awareness on women's health and much, much broader use of hormone therapy, and so it's become less of a specialist thing, and it's becoming more mainstream. So that is shifting rapidly. But the thing that's shifting on top of that is, you know, you're seeing online, you know, women's health, you know, centers or care DTC models. And that, I think, sort of, you know, aligns pretty well with what we're seeing in the obesity market where, you know, Lilly Direct and other models like that are proving to be extremely effective ways of getting drugs out to patients quickly. Um, so we like, we like thinking about that market because there you've got like to do that effectively. You need something you can self-diagnose. You need something where if you refer to a telehealth, you can get a diagnosis without a physical exam. You need a large therapeutic window and a lot of safety. And then you need it to be something that is widely applicable enough that you've got sort of a consumer dynamic and that reinforcement. And if you look at all the products out there, I'm like, you've got obesity, maybe you have hair, migraine, maybe a little bit, but, you know, ABCEL 635 and menopause in women's health feels like a slam dunk for that type of model. So we think that that could be a very exciting way to get this out to patients. And I see we're running out of time, but I'll just, I'll highlight that on the last earnings call, we also mentioned that we've got a half-life extended version of ABCEL 635 called ABCEL 992. It's an engineered analog for less frequent dosing. In addition to making sure that we're the frontrunner on all angles on this opportunity, it also is a product that lowers the cost of goods very significantly, and that means that you could have price flexibility to get even into the mode where you have a self-pay model rather than a reimbursed model. We haven't decided to do that, but having that flexibility and that optionality I think could be very important, not just in the U.S., but also in Europe and South America and the rest of the world.
Alice Nettleton, Analyst — UBS
Great. And I don't know how much you've shared about your long-term strategy for this in terms of wanting to partner the asset, but it seems like top of the list in terms of... What qualities for your partner to have would be to have an established DTC platform?
Carl Hansen, CEO
Yeah, if we were going to partner it, I think that would be very, very high on the list. You know, in terms of partnering, maybe I'll just back up to what we're trying to build at Abcelro. So we're trying to build a company that can repeatedly, you know, invent breakthrough medicines, develop them, and commercialize them. And to do that, you need a capability. We've got that in place. You need a pipeline that's exciting, and you need to find your winning drug. And I think with this recent data, we think we have a winning drug, and we're going to be holding on to it jealously and making sure we're putting our shoulder into it to make the most of it. So at this point, we are not at all looking for partnering. We're looking to take it into phase three. And then we're thinking very seriously about the commercialization side, and is this something we would do on our own? We may well, and we've got some opportunity to set it up. It could also be that the right partner would help to really... Electrify that and really turn it up a notch, and we'd certainly be open to that, but when you're building a company, you have to make sure you've got a path on your own steam, and that's what we're focused on.
Alice Nettleton, Analyst — UBS
Definitely. Well, thank you so much for joining us today. I think it's been a great conversation, and thank you, everybody.